92 results on '"Vanderpoel J"'
Search Results
2. Figure Drawing: Neck, Throat, and Shoulders
3. Figure Drawing: The Arm
4. On Some Miniatures, by Miss Martha S. Baker
5. EE145 Real-World Healthcare Resource Use, Costs, and Treatment Patterns in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with Different Epidermal Growth Factor Receptor Mutation Types
6. Factors associated with ‘caregiver burden’ for atrial fibrillation patients
7. Notes on Figure Drawing by J. H. Vanderpoel
8. Figure Drawing, Mouth and Ear
9. The Head
10. Figure Drawing, the Head
11. II. Figure Drawing, the Eye
12. The Mouth
13. III. Figure Drawing, the Nose
14. Figure Drawing: Nose and Mouth
15. The Permanent Collections in the Museum of the Art Institute of Chicago. V. The Old Dutch Masters
16. The Antiquarians' Loan Exhibition of Old and Modern Masters
17. Health care costs by level of adherence for infliximab patients with crohn’s disease
18. Relative adherence across sites-of-care for infliximab patients with crohn’s disease
19. Comparison of clinical and cost characteristics among patients with inflammatory bowel disease across different sites of care
20. PSY58 Racial and Ethnic Differences in Patient Perceptions of Intravenous Biologic Therapy Among Currently Treated Patients With Immunology Conditions
21. PSY24 Association of Patient Cost or Reimbursement Challenges With Health Care Resource Utilization, Quality of Life, and Work Productivity Among Patients With Inflammatory Bowel Disease
22. Association of treatment satisfaction with healthcare resource utilization, quality of life and work productivity among patients with Inflammatory Bowel Disease currently using biologic treatment
23. Assessment of infliximab utilization for Crohnʼs disease and Ulcerative Colitis patients across different sites-of-care
24. Infliximab utilization patterns within an alternate site of care setting among patients with Inflammatory Bowel Disease
25. Stability of infliximab dosing among individuals with Crohnʼs Disease: Results from a mid-atlantic healthplan
26. Perceived Benefits of Intravenous (IV) Biologic Therapy Among Patients with Inflammatory Bowel Disease (IBD)
27. Patient Perceptions and Experiences with Sites of Care (SOCs) Among Patients with Immunology Conditions Currently Using Intravenous (IV) Biologic Therapy
28. Factors Influencing Medication and Site of Care (SOC) Selection Among Patients with Inflammatory Bowel Disease (IBD) Currently Receiving Intravenous (IV) Biologic Therapy
29. PSY62 PERCEIVED BENEFITS AND DISADVANTAGES OF INTRAVENOUS (IV) BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS
30. PSY67 REASONS FOR INITIATING INTRAVENOUS BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS: SUBSET ANALYSIS OF PRIOR SUBCUTANEOUS INJECTION (SQ) USERS AND IMPLICATIONS FOR SHARED DECISION MAKING
31. Cost-effectiveness of immunomodulators versus infliximab for adults with moderate-to-severe ulcerative colitis.
32. Gastrointestinal-related diagnostic procedures in patients with Inflammatory Bowel Disease before and after Infliximab Initiation
33. PGI24 - Health care costs by level of adherence for infliximab patients with crohn’s disease
34. PGI23 - Relative adherence across sites-of-care for infliximab patients with crohn’s disease
35. PSY62 - Comparison of clinical and cost characteristics among patients with inflammatory bowel disease across different sites of care
36. Biologic Absorption of Insolubilized Gelatin Films
37. PGI24 Health care costs by level of adherence for infliximab patients with crohn’s disease
38. PGI23 Relative adherence across sites-of-care for infliximab patients with crohn’s disease
39. PSY62 Comparison of clinical and cost characteristics among patients with inflammatory bowel disease across different sites of care
40. Impact of next-generation sequencing vs polymerase chain reaction testing on payer costs and clinical outcomes throughout the treatment journeys of patients with metastatic non-small cell lung cancer.
41. Disparities in Lung Cancer: A Targeted Literature Review Examining Lung Cancer Screening, Diagnosis, Treatment, and Survival Outcomes in the United States.
42. Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer.
43. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type.
44. Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis.
45. Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
46. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer.
47. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
48. Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users.
49. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
50. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.